Activating Compound | Comment | Organism | Structure |
---|---|---|---|
additional information | the ERalpha receptor upregulates enzyme expression, hyperforin induces the enzyme | Homo sapiens |
Cloned (Comment) | Organism |
---|---|
FMO1, DNA and amino acid sequence determination and analysis, phylogenetic analysis | Homo sapiens |
FMO2, DNA and amino acid sequence determination and analysis, sequence comparisons and phylogenetic analysis | Homo sapiens |
FMO3, DNA and amino acid sequence determination and analysis, the gene maps to the long arm of chromosome 1, phylogenetic analysis | Homo sapiens |
FMO4, DNA and amino acid sequence determination and analysis, phylogenetic analysis, the gene maps to the long arm of chromosome 1, genotyping and alternative splicing variants, overview | Homo sapiens |
FMO5, the gene encoding the enzyme is located at 1q21.1, not in the FMO gene cluster at 1q24.3, DNA and amino acid sequence determination and analysis, phylogenetic analysis | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
A52T | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
C530L | naturally occuring single nucleotide polymorphism of FMO2 | Homo sapiens |
D132H | naturally occuring single nucleotide polymorphism of FMO3, the mutant shows substrate-dependent reduced activity | Homo sapiens |
D198E | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
D36G | naturally occuring single nucleotide polymorphism of FMO2 | Homo sapiens |
E158K | naturally occuring single nucleotide polymorphism of FMO3, the mutation slightly affects enzyme activity, substrate-dependent reduced activity | Homo sapiens |
E158K/E308G | naturally occuring single nucleotide polymorphism of FMO3, the mutation affects enzyme activity, substrate-dependent reduced activity | Homo sapiens |
E24D | naturally occuring single nucleotide polymorphism of FMO3, the mutant shows reduced activity | Homo sapiens |
E305X | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
E308G | naturally occuring single nucleotide polymorphism of FMO3, the mutation slightly affects enzyme activity, substrate-dependent reduced activity | Homo sapiens |
E314G | naturally occuring single nucleotide polymorphism of FMO2 | Homo sapiens |
E314X | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
E32K | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
E339Q | naturally occuring single nucleotide polymorphism of FMO4 | Homo sapiens |
E362Q | naturally occuring single nucleotide polymorphism of FMO3 | Homo sapiens |
F182S | naturally occuring single nucleotide polymorphism of FMO2 | Homo sapiens |
F69Y | naturally occuring single nucleotide polymorphism of FMO2 | Homo sapiens |
F81S | naturally occuring single nucleotide polymorphism of FMO2 | Homo sapiens |
G148X | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
G180V | naturally occuring single nucleotide polymorphism of FMO3, the mutant is similar to the wild-type enzyme | Homo sapiens |
G475D | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
G503R | naturally occuring single nucleotide polymorphism of FMO3 | Homo sapiens |
H97Q | naturally occuring single nucleotide polymorphism of FMO1, the mutant enzyme is similar to the wild-type enzyme | Homo sapiens |
I199T | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
I303T | naturally occuring single nucleotide polymorphism of FMO1, the mutant enzyme is similar to the wild-type enzyme | Homo sapiens |
I303V | naturally occuring single nucleotide polymorphism of FMO1, the mutant enzyme is similar to the wild-type enzyme | Homo sapiens |
I37T | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
I37T | naturally occuring single nucleotide polymorphism of FMO4 | Homo sapiens |
I468M | naturally occuring single nucleotide polymorphism of FMO3 | Homo sapiens |
K416N | naturally occuring single nucleotide polymorphism of FMO3, the mutant shows reduced activity | Homo sapiens |
L360P | naturally occuring single nucleotide polymorphism of FMO3, the mutant shows increased activity | Homo sapiens |
M260V | naturally occuring single nucleotide polymorphism of FMO3 | Homo sapiens |
M434I | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
M66I | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
M82T | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
additional information | naturally occuring mutations, including silent mutations, genotyping, overview | Homo sapiens |
N114S | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
N413K | naturally occuring single nucleotide polymorphism of FMO2, the mutant is similar to the wild-type enzyme | Homo sapiens |
N61K | naturally occuring single nucleotide polymorphism of FMO3, the mutant shows reduced activity | Homo sapiens |
N61S | loss of function mutation of FMO3 results in trimethylaminuria or fish-odor-syndrome, the mutant enzyme is incapable of metabolizing trimethylamine to its non-odorous N-oxide, nuta this mutant is still active with methimazole, phenotype, overview | Homo sapiens |
P153L | loss of function mutation of FMO3 results in trimethylaminuria or fish-odor-syndrome, the mutant enzyme is incapable of metabolizing trimethylamine to its non-odorous N-oxide, phenotype, overview | Homo sapiens |
P153L | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
P457L | naturally occuring single nucleotide polymorphism of FMO4 | Homo sapiens |
Q470X | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
Q472X | naturally occuring single nucleotide polymorphism of FMO2, inactive mutant | Homo sapiens |
R205C | naturally occuring single nucleotide polymorphism of FMO3, the mutant shows reduced activity | Homo sapiens |
R223Q | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
R223Q | naturally occuring single nucleotide polymorphism of FMO1 | Homo sapiens |
R238P | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
R238Q | naturally occuring single nucleotide polymorphism of FMO2 | Homo sapiens |
R249X | naturally occuring single nucleotide polymorphism of FMO2, probably inactive mutant | Homo sapiens |
R378L | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
R391T | naturally occuring single nucleotide polymorphism of FMO2 | Homo sapiens |
R500X | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
R502X | naturally occuring single nucleotide polymorphism of FMO1, the mutant shows substrate-dependent reduced activity compared to the wild-type enzyme | Homo sapiens |
R506S | naturally occuring single nucleotide polymorphism of FMO4 | Homo sapiens |
R51G | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
S195L | naturally occuring single nucleotide polymorphism of FMO2, inactive mutant | Homo sapiens |
T201K | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
T308S | naturally occuring single nucleotide polymorphism of FMO4 | Homo sapiens |
V143E | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
V257M | naturally occuring single nucleotide polymorphism of FMO3, the mutant shows slightly reduced activity | Homo sapiens |
V277A | naturally occuring single nucleotide polymorphism of FMO3 | Homo sapiens |
V323A | naturally occuring single nucleotide polymorphism of FMO4 | Homo sapiens |
V58I | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
W388X | naturally occuring mutation causing trimethylaminuria or fish-odor-syndrome | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
additional information | FMO5 is downregulated in type 2 diabetes | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
microsome | - |
Homo sapiens | - |
- |
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
60047 | - |
x * 60047, sequence calcualtion | Homo sapiens |
63338 | - |
x * 63338, sequence calculation | Homo sapiens |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | Homo sapiens | FMO2 catalyzes the S-oxygenation of organophosphates representing a detoxification pathway | ? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P31512 | FMO4 | - |
Homo sapiens | P31513 | FMO3 | - |
Homo sapiens | P49326 | FMO5 | - |
Homo sapiens | Q01740 | FMO1 | - |
Homo sapiens | Q99518 | FMO2 | - |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
blood vessel | - |
Homo sapiens | - |
intestine | - |
Homo sapiens | - |
kidney | - |
Homo sapiens | - |
liver | fetal and adult | Homo sapiens | - |
liver | birth is necessary but not sufficient for FMO3 onset in the liver, it occurs between week 3 and 10 after birth | Homo sapiens | - |
liver | high level expression in adult liver | Homo sapiens | - |
lung | FMO2 mainly | Homo sapiens | - |
additional information | broad tissue distribution, overview | Homo sapiens | - |
additional information | tissue-specific and devlopmental expression of FMO3, overview | Homo sapiens | - |
additional information | tissue-specific expression of FMO1, overview | Homo sapiens | - |
additional information | tissue-specific expression of FMO2, overview | Homo sapiens | - |
additional information | tissue-specific expression of FMO5, overview, the enzyme is increased in ERalpha-positive tumors | Homo sapiens | - |
myocardium | FMO1, expression profiling in tissue from patients with atrial fibrillation | Homo sapiens | - |
prostate gland | - |
Homo sapiens | - |
skeletal muscle | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
amphetamine + NADPH + H+ + O2 | an antipsychotic agent, is converted to the hydroxylamine | Homo sapiens | ? | - |
? | |
benzydamine + NADPH + H+ + O2 | a nonsteroidal antiinflammatory drug, is converted to the N-oxide | Homo sapiens | benzydamine N-oxide + NADP+ + H2O | - |
? | |
chlorpromazine + NADPH + H+ + O2 | a dopemaine D2 antagonist | Homo sapiens | chlorpromazine N-oxide + NADP+ + H2O | - |
? | |
clozapine + NADPH + H+ + O2 | an antipsychotic agent, is converted to the N-oxide | Homo sapiens | clozapine N-oxide + NADP+ + H2O | - |
? | |
deprenyl + NADPH + H+ + O2 | a monoamine oxidase type B inhibitor, is converted to the hydroxylamine | Homo sapiens | ? | - |
? | |
disulfoton + NADPH + H+ + O2 | a thioether-containing organophosphate insecticide | Homo sapiens | ? | - |
? | |
esonarimod + NADPH + H+ + O2 | a antirheumatic drug, is converted to the S-oxide | Homo sapiens | S-methyl esonarimod + NADP+ + H2O | - |
? | |
ethionamide + NADPH + H+ + O2 | an antibiotic agent | Homo sapiens | ? | - |
? | |
ethionamide + NADPH + H+ + O2 | an antibiotic agent | Homo sapiens | ethionamide N-oxide + NADP+ + H2O | - |
? | |
imipramine + NADPH + H+ + O2 | an antidepressant, is converted to the N-oxide | Homo sapiens | imipramine N-oxide + NADP+ + H2O | - |
? | |
itopride + NADPH + H+ + O2 | a dopamine D2 receptor antagonist, is converted to the N-oxide | Homo sapiens | itopride N-oxide + NADP+ + H2O | - |
? | |
K11777 + NADPH + H+ + O2 | a cysteine protease inhibitor against Trypanosoma cruzi, is converted to the N-oxide | Homo sapiens | K11777 N-oxide + NADP+ + H2O | - |
? | |
L-methionine + NADPH + H+ + O2 | - |
Homo sapiens | ? | - |
? | |
methamphetamine + NADPH + H+ + O2 | a psychostimulant, is converted to the hydroxylamine | Homo sapiens | ? | - |
? | |
methamphetamine + NADPH + H+ + O2 | a psychostimulant, is converted to the hydroxylamine | Homo sapiens | methamphetamine N-oxide + NADP+ + H2O | - |
? | |
methimazole + NADPH + H+ + O2 | a thyroperoxidase inhibitor | Homo sapiens | ? | - |
? | |
methimazole + NADPH + H+ + O2 | a thyroperoxidase inhibitor, is converted to the S-oxide | Homo sapiens | ? | - |
? | |
methimazole + NADPH + H+ + O2 | an thyroperoxidase inhibitor, is converted to the S-oxide | Homo sapiens | ? | - |
? | |
methimazole + NADPH + H+ + O2 | an thyroperoxidase inhibitor, is converted to the S-oxide | Homo sapiens | methimazole N-oxide + NADP+ + H2O | - |
? | |
MK-0767 methyl sulfide + NADPH + H+ + O2 | a peroxisome proliferator receptor activator, is converted to the S-oxide | Homo sapiens | ? | - |
? | |
additional information | FMO2 catalyzes the S-oxygenation of organophosphates representing a detoxification pathway | Homo sapiens | ? | - |
? | |
N-deacetyl ketoconazole + NADPH + H+ + O2 | an antifungal agent, is converted to the N-hydroxyl | Homo sapiens | ? | - |
? | |
N-deacetyl ketoconazole + NADPH + H+ + O2 | an antifungal agent, is converted to the N-hydroxyl | Homo sapiens | N-deacetyl ketoconazole N-oxide + NADP+ + H2O | - |
? | |
nicotine + NADPH + H+ + O2 | a stimulant, is converted to the trans-N-oxide | Homo sapiens | nicotine N-oxide + NADP+ + H2O | - |
? | |
olopatadine + NADPH + H+ + O2 | an antihistamininc drug, is converted to the N-oxide | Homo sapiens | olopatadine N-oxide + NADP+ + H2O | - |
? | |
orphenadrine + NADPH + H+ + O2 | an anticholinergic drug | Homo sapiens | orphenadrine N-oxide + NADP+ + H2O | - |
? | |
phorate + NADPH + H+ + O2 | a thioether-containing organophosphate insecticide | Homo sapiens | ? | - |
? | |
pyrazolacridine + NADPH + H+ + O2 | an antitumor drug, is converted to the N-oxide | Homo sapiens | pyrazolacridine N-oxide + NADP+ + H2O | - |
? | |
ranitidine + NADPH + H+ + O2 | an antihistamininc drug, is converted to the N-oxide and/or S-oxide | Homo sapiens | ? | - |
? | |
S-allyl-L-cysteine + NADPH + H+ + O2 | - |
Homo sapiens | ? | - |
? | |
S-methyl esonarimod + NADPH + H+ + O2 | a cytokine production inhibitor, is converted to the S-oxide | Homo sapiens | ? | - |
? | |
S-methyl esonarimod + NADPH + H+ + O2 | an cytokine production inhibitor, is converted to the S-oxide | Homo sapiens | S-methyl esonarimod S-oxide + NADP+ + H2O | - |
? | |
S16020 + NADPH + H+ + O2 | a topoisomerase II inhibitor and antitumor drug, is converted to the N-oxide | Homo sapiens | S16020 N-oxide + NADP+ + H2O | - |
? | |
SNI-2011 + NADPH + H+ + O2 | a muscarinic receptor antagonist, is converted to the N-oxide | Homo sapiens | ? | - |
? | |
sulindac sulfide + NADPH + H+ + O2 | a nonsteroidal antiinflammatory drug, is converted to the S-oxide | Homo sapiens | sulindac + NADP+ + H2O | - |
? | |
tamoxifen + NADPH + H+ + O2 | an estrogen receptor modulator, is converted to the N-oxide | Homo sapiens | tamoxifen N-oxide + NADP+ + H2O | - |
? | |
tazarotenic acid + NADPH + H+ + O2 | a retinoic acid receptor modulator, is converted to the S-oxide | Homo sapiens | ? | - |
? | |
tazarotenic acid + NADPH + H+ + O2 | an retinoic acid receptor modulator, is converted to the S-oxide | Homo sapiens | tazarotenate N-oxide + NADP+ + H2O | - |
? | |
thiacetazone + NADPH + H+ + O2 | a anti-tubercular drug, high activity | Homo sapiens | ? | - |
? | |
thiacetazone + NADPH + H+ + O2 | an antibiotic agent, is converted to the sulfinic acid/carbodiimide | Homo sapiens | ? | - |
? | |
thiacetazone + NADPH + H+ + O2 | an antibiotic agent, is converted to the sulfinic acid/carbodiimide | Homo sapiens | thiacetazone N-oxide + NADP+ + H2O | - |
? | |
xanomeline + NADPH + H+ + O2 | a muscarinic receptor antagonist, is converted to the N-oxide | Homo sapiens | xanomeline N-oxide + NADP+ + H2O | - |
? |
Subunits | Comment | Organism |
---|---|---|
? | x * 60047, sequence calcualtion | Homo sapiens |
? | x * 63338, sequence calculation | Homo sapiens |
Synonyms | Comment | Organism |
---|---|---|
FMO | - |
Homo sapiens |
FMO1 | - |
Homo sapiens |
FMO2 | - |
Homo sapiens |
FMO4 | - |
Homo sapiens |
Cofactor | Comment | Organism | Structure |
---|---|---|---|
FAD | binding site structure containing a GXGXXG motif, overview | Homo sapiens | |
FAD | binding site structure containing an GXGXXG motif, overview | Homo sapiens | |
NADPH | binding site structure containing a GXGXXG motif, overview | Homo sapiens | |
NADPH | binding site structure containing an GXGXXG motif, overview | Homo sapiens |